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EDITORIAL
Split-Course Radiotherapy for Poor-Risk Stage III Lung
Cancer
Striking the Right Balance or History Regurgitated?
Jeffrey A. Bogart, MD
In this issue of Journal of Thoracic Oncology, Gielda et al.1 report their extensivesingle-institution experience treating stage III non-small cell lung cancer (NSCLC) with
split-course radiotherapy (SCR) concurrent with chemotherapy. By far, the most interest-
ing observation is the favorable outcome for patients with poor-risk features such as
pretreatment weight loss and poor performance status. In fact, the median survival of the
poor-risk cohort numerically eclipsed that of standard-risk patients. Although the authors
suggest that these results were not likely influenced by selection of a favorable cohort of
poor-risk patients, whether selection bias, happenstance, or the treatment approach itself
is responsible for outcomes is a matter for speculation. Nevertheless, these data would
suggest that a reassessment of SCR may be warranted.
The history of SCR is quite muddied with the mention of SCR (in the curative
setting) often reflexively met with criticism in the radiotherapy community. The intent of
including rest days during the course of radiotherapy is to allow for recovery of normal
tissues and improve the tolerability of intensive therapy. However, serious concerns have
been raised because the rest period may facilitate accelerated repopulation of resistant
tumor clones with a resultant loss of local tumor control.2 Clinical evidence supporting a
detrimental impact of radiation treatment breaks is largely circumstantial and is based in
part on data from patients who required unplanned radiation treatment interruptions. This
association has been observed in several epithelial malignancies. For example, a retro-
spective review of Radiation Therapy Oncology Group (RTOG) studies in NSCLC
demonstrated worse outcomes when the time to complete radiotherapy was protracted,3
although this observation may simply emphasize that patients not able to tolerate
continuous course treatment do poorly. Prospective randomized trials that tested “accel-
erated” radiotherapy regimens with a planned treatment break have been interpreted as
further indirect evidence of the negative impact of SCR—the assumption being that the
accelerated regimen would have been beneficial if a break had not been given. A
frequently cited example is the differing results of trials assessing twice-daily radiotherapy
(BID RT) versus conventional radiotherapy for limited-stage small cell lung cancer:
continuous BID RT improved survival on Intergroup trial 0096, whereas a North Central
Cancer Treatment Group trial did not find a benefit for split-course BID RT.4,5 There are
less data available describing the impact of a planned treatment break when standard
fractionation is given (2 Gy daily fractions) simultaneously with systemic chemother-
apy. The bulk of experience in this regard comes from the treatment of anal carcinoma,
which appears to be a more radiosensitive tumor than NSCLC, with conflicting reports in
sequential phase II trials as to the impact of a planned treatment break.6,7 Despite the
strong bias against the use of SCR, an overview of 13 randomized studies and numerous
additional retrospective studies found no clinically relevant differences between contin-
uous radiotherapy and SCR.8
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Unlike poor-risk patients, outcomes for standard-risk
patients in the current report are in-line with results expected
with other approaches. This underscores the notion that the
therapeutic balance is not meaningfully shifted for this pop-
ulation. Although the split-course approach may be associ-
ated with less acute toxicity (particularly esophagitis) than
traditional combined modality treatment, standard-risk pa-
tients usually recover fully from severe acute esophagitis
without long-term sequelae. On the other hand, poor-risk
patients may have less reserve capacity and more difficulty
overcoming severe acute toxicity. Sequential studies con-
ducted by the Southwest Oncology Group support the con-
tention that poor-risk patients can only be pushed so hard
before diminishing returns are seen. An initial Southwest
Oncology Group trial assessing concurrent chemotherapy and
continuous fractionated radiotherapy reported a median sur-
vival of 13 months, encouraging for a poor-risk population,
but a follow-up protocol adding adjuvant paclitaxel chemo-
therapy resulted in increased toxicity and worse survival.9,10
So the hypothesis that recovery from acute reactions during a
planned break could substantially shift the therapeutic ratio
would appear to be tenable in the poor-risk population. One
of the most remarkable findings in the current report is the
high percentage of poor-risk patients completing the entire
planned course of chemotherapy and radiotherapy.
Larger population-based studies also seem to empha-
size the delicate balance that must be respected when design-
ing treatment strategies for poor-risk patients. In a report
from Davidoff et al.,11 published in last issue of the Journal,
Surveillance, Epidemiology, and End Results data for more
than 6000 patients older than 65 years with stage III NSCLC
were analyzed. Despite using a conservative definition of
“elderly,” patients treated with concurrent chemoradiother-
apy had increased mortality compared with treatment with
radiotherapy alone. On the other hand, sequential chemother-
apy followed by radiotherapy was associated with improved
survival compared with radiotherapy alone. These sentiments
were echoed in a quality-adjusted survival analysis of more
than 900 patients enrolled on RTOG prospective studies for
NSCLC between 1983 and 1995. Patients less than 70 years
had improved survival with more aggressive therapy,
whereas older patients fared best with standard radiotherapy
alone.12 In stark contrast to these reports are the results from
a landmark prospective phase III study, RTOG 9410, com-
paring sequential and concurrent chemoradiotherapy in lo-
cally advanced NSCLC, which suggest that patients aged 70
and older actually derive the greatest benefit from concurrent
therapy.13 These contradictory results strongly caution
against using chronologic age alone in selecting a treatment
approach for patients with locally advanced NSCLC.
Whether SCR has sufficient merit to carry forward with
new prospective trials in the 21st century is debatable. In
addition to biologic concerns, a key drawback of the SCR
program is the time to complete therapy (approximately 70
days). This can place a logistical burden on poor-risk patients,
who frequently have multiple comorbidities, and the ex-
tended course of treatment may be associated with increased
costs. We are now in an era where advances in radiotherapy
technology, such as 3D planning, image guided therapy, and
respiratory gating, have greatly improved the ability to con-
form the radiation dose to the intended target while protecting
surrounding normal structures. These advances have facili-
tated an evolution toward delivering fewer treatments in a
shorter time period. Stereotactic body radiotherapy, used in
early stage NSCLC, is the most extreme example, but trials of
hypofractionated radiotherapy for stage III disease are
planned in both the RTOG and Cancer and Leukemia Group
B. Other novel strategies under investigation aim to exploit
the biologic differences between cancer cells and normal cells
by combining radiotherapy with molecular targeted agents
that preferentially sensitize tumor.14,15 In the end, it may be
more rewarding to work toward developing regimens that are
less likely to cause toxicity severe enough to require inter-
ruptions of therapy rather than reducing treatment intensity
for the sake of allowing patients to complete a prescribed
course of therapy.
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